氯硝西泮
左乙拉西坦
维加巴丁
心律失常
癫痫痉挛
儿科
托吡酯
全球发育迟缓
医学
癫痫
丙戊酸
脑病
肌阵挛性癫痫
促肾上腺皮质激素
强的松
心理学
麻醉
内科学
精神科
抗惊厥药
遗传学
生物
激素
基因
表型
标识
DOI:10.3389/fneur.2022.889167
摘要
Developmental and epileptic encephalopathy 91 (DEE91; OMIM#617711) is a severe neurodevelopmental disorder caused by heterozygous PPP3CA variants. To the best of our knowledge, only a few DEE91 cases have been reported.This study reports a boy who experienced recurrent afebrile convulsions and spasms at the age of 2 months. After being given multiple antiepileptic treatments with levetiracetam, adrenocorticotropic hormone (ACTH), prednisone, topiramate, and clonazepam, his seizures were not completely relieved. At the age of 4 months, the patient exhibited delayed neuromotor development and difficulty in feeding; at the age of 6 months, he was diagnosed with developmental regression with recurrent spasms and myoclonic seizures that could respond to vigabatrin. At the age of 1 year and 4 months, the patient showed profound global developmental delay (GDD) with intermittent absence seizures. Whole-exome sequencing (WES) identified a novel loss-of-function variant c.1258_1259insAGTG (p. Val420Glufs*32) in PPP3CA.This finding expands the genetic spectrum of the PPP3CA gene and reinforces the theory that DEE91-associated truncating variants cluster within a 26-amino acid region in the regulatory domain (RD) of PPP3CA.
科研通智能强力驱动
Strongly Powered by AbleSci AI